Fig. 3

CAF-related signatures showed stronger poor-prognosis association in those patients with advanced colon tumors than in initial stages: Comparison of the prognosis of the colon tumors (1235 samples) in initial stages I and II (660 samples) and in advanced stages III and IV (575 samples). The risk assigned to each subgroup using 3 different gene signatures is shown in (a). The survival analysis examined the two sub-groups of samples, in stages I & II (b) or in stages III & IV (c), using the combination of both top 50 + 50 gene signatures. CAF-related signatures showed stronger poor-prognosis association in those patients with CMS4 than in CMS1–3. Comparison of the prognosis of the colon tumors classified following the consensus molecular subtypes (CMS1,2,3,4) defined by Guinney et al. [5, 11], divided into two groups: 593 samples of subtypes CMS1,2,3 and 237 samples of subtype CMS4. d Risk assigned to each of these 2 groups using the top 50 genes of signature 67, the top 50 of signature 596 and the top 50 + 50 from the two combined. Survival analysis using the combined signature for the 2 groups of samples separated: CMS1,2,3 (e) and CMS4 (f)